1-6 of 6
Richard S. Geary
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Combination with Gemcitabine in Patients with Advanced Cancer

Free
Alex A. Adjei, Grace K. Dy, Charles Erlichman, Joel M. Reid, Jeff A. Sloan, Henry C. Pitot, Steven R. Alberts, Richard M. Goldberg, Lorelei J. Hanson, Pamela J. Atherton, Tanya Watanabe, Richard S. Geary, Jon Holmlund, F. Andrew Dorr
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (1): 115–123.
Published: 01 January 2003
View articletitled, A Phase I Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Combination with Gemcitabine in Patients with Advanced Cancer
Open the PDF for A Phase I Trial of ISIS 2503, an Antisense Inhibitor of H-ras, in Combination with Gemcitabine in Patients with Advanced Cancer in another window
Journal Articles

A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-refractory Prostate Cancer

Free
Anthony W. Tolcher, Leonard Reyno, Peter M. Venner, Scott D. Ernst, Malcolm Moore, Richard S. Geary, Kim Chi, Sean Hall, Wendy Walsh, Andrew Dorr, Elizabeth Eisenhauer
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (8): 2530–2535.
Published: 01 August 2002
View articletitled, A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-refractory Prostate Cancer
Open the PDF for A Randomized Phase II and Pharmacokinetic Study of the Antisense Oligonucleotides ISIS 3521 and ISIS 5132 in Patients with Hormone-refractory Prostate Cancer in another window
Journal Articles

Phase II Randomized Study of ISIS 3521 and ISIS 5132 in Patients with Locally Advanced or Metastatic Colorectal Cancer: A National Cancer Institute of Canada Clinical Trials Group Study

Free
M. Christine Cripps, Alvaro T. Figueredo, Amit M. Oza, Marianne J. Taylor, Anthony L. Fields, John T. Holmlund, Lynn W. McIntosh, Richard S. Geary, Elizabeth A. Eisenhauer
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (7): 2188–2192.
Published: 01 July 2002
View articletitled, Phase II Randomized Study of ISIS 3521 and ISIS 5132 in Patients with Locally Advanced or Metastatic Colorectal Cancer: A National Cancer Institute of Canada Clinical Trials Group Study
Open the PDF for Phase II Randomized Study of ISIS 3521 and ISIS 5132 in Patients with Locally Advanced or Metastatic Colorectal Cancer: A National Cancer Institute of Canada Clinical Trials Group Study in another window
Journal Articles

Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-α Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer

Free
Sridhar Mani, Charles M. Rudin, Katie Kunkel, Jon T. Holmlund, Richard S. Geary, Hedy L. Kindler, F. Andrew Dorr, Mark J. Ratain
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (4): 1042–1048.
Published: 01 April 2002
View articletitled, Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-α Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer
Open the PDF for Phase I Clinical and Pharmacokinetic Study of Protein Kinase C-α Antisense Oligonucleotide ISIS 3521 Administered in Combination with 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer in another window
Journal Articles

A Phase I Trial of c-Raf Kinase Antisense Oligonucleotide ISIS 5132 Administered as a Continuous Intravenous Infusion in Patients with Advanced Cancer

Free
C. Casey Cunningham, Jon T. Holmlund, Joan H. Schiller, Richard S. Geary, T. Jesse Kwoh, Andrew Dorr, John Nemunaitis
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (5): 1626–1631.
Published: 01 May 2000
View articletitled, A Phase I Trial of c-Raf Kinase Antisense Oligonucleotide ISIS 5132 Administered as a Continuous Intravenous Infusion in Patients with Advanced Cancer
Open the PDF for A Phase I Trial of c-Raf Kinase Antisense Oligonucleotide ISIS 5132 Administered as a Continuous Intravenous Infusion in Patients with Advanced Cancer in another window
Journal Articles

Phase I Study of an Antisense Oligonucleotide to Protein Kinase C-α (ISIS 3521/CGP 64128A) in Patients with Cancer

Free
Alan R. Yuen, Joanne Halsey, George A. Fisher, Jon T. Holmlund, Richard S. Geary, T. Jesse Kwoh, Andrew Dorr, Branimir I. Sikic
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (11): 3357–3363.
Published: 01 November 1999
View articletitled, Phase I Study of an Antisense Oligonucleotide to Protein Kinase C-α (ISIS 3521/CGP 64128A) in Patients with Cancer
Open the PDF for Phase I Study of an Antisense Oligonucleotide to Protein Kinase C-α (ISIS 3521/CGP 64128A) in Patients with Cancer in another window